Early initiation of L-dopa therapy enables stable development of executive function in tetrahydrobiopterin (BH4) deficiency

Yoko Tanaka, Motoichiro Kato, Taro Muramatsu, Fumie Saito, Seiji Sato, Nobutake Matsuo, Haruo Shintaku, Yoshiyuki Okano, Hiroshi Kondo, Tatsushi Nukazawa

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

Executive function (EF) has been presumed to be mediated by the dopaminergic system in the prefrontal cortex. However, little is known about the early development of this function and the roles dopamine plays in it. Tetrahydrobiopterin (BH4) deficiencies are genetic disorders affecting catecholamine and serotonin biosynthesis which, if untreated, result in motor and cognitive symptoms including impairment of EF. A comprehensive neuropsychological test battery was administered to six participants with BH4 deficiency (four males, two females, mean Full-scale intelligence quotient [FIQ] 63.8 [SD 14.7]); all were on replacement therapy with L-dopa and BH4, but time of initiation of treatment varied. Age range (median) was 28 days to 41 years (2y 6mo) at initiation of treatment and 10 to 47 years (19y) at follow-up. On non-EF tests, performance agreed with those of IQ-matched controls (four males, two females; mean age 16y 6mo [SD 6mo]; mean FIQ 62.3 [SD 13.4]). On EF tests those who initiated treatment after 2 years 6 months of age performed poorly. In patients with BH4 deficiency, replacement therapy should be started in the first weeks or months of life. Patients diagnosed before the age of 2 years 6 months obtain normal EF, which suggests dopamine may play a critical role in ensuring stable development of EF in early life.

Original languageEnglish
Pages (from-to)372-376
Number of pages5
JournalDevelopmental Medicine and Child Neurology
Volume49
Issue number5
DOIs
Publication statusPublished - 2007 May

Fingerprint

Phenylketonurias
Executive Function
Levodopa
Intelligence
Dopamine
Therapeutics
Neurobehavioral Manifestations
Inborn Genetic Diseases
Neuropsychological Tests
Prefrontal Cortex
Catecholamines
Serotonin

ASJC Scopus subject areas

  • Clinical Neurology
  • Pediatrics, Perinatology, and Child Health
  • Neuroscience(all)

Cite this

Early initiation of L-dopa therapy enables stable development of executive function in tetrahydrobiopterin (BH4) deficiency. / Tanaka, Yoko; Kato, Motoichiro; Muramatsu, Taro; Saito, Fumie; Sato, Seiji; Matsuo, Nobutake; Shintaku, Haruo; Okano, Yoshiyuki; Kondo, Hiroshi; Nukazawa, Tatsushi.

In: Developmental Medicine and Child Neurology, Vol. 49, No. 5, 05.2007, p. 372-376.

Research output: Contribution to journalArticle

Tanaka, Yoko ; Kato, Motoichiro ; Muramatsu, Taro ; Saito, Fumie ; Sato, Seiji ; Matsuo, Nobutake ; Shintaku, Haruo ; Okano, Yoshiyuki ; Kondo, Hiroshi ; Nukazawa, Tatsushi. / Early initiation of L-dopa therapy enables stable development of executive function in tetrahydrobiopterin (BH4) deficiency. In: Developmental Medicine and Child Neurology. 2007 ; Vol. 49, No. 5. pp. 372-376.
@article{1db879d92a7d442f9cf14cc93b2cd573,
title = "Early initiation of L-dopa therapy enables stable development of executive function in tetrahydrobiopterin (BH4) deficiency",
abstract = "Executive function (EF) has been presumed to be mediated by the dopaminergic system in the prefrontal cortex. However, little is known about the early development of this function and the roles dopamine plays in it. Tetrahydrobiopterin (BH4) deficiencies are genetic disorders affecting catecholamine and serotonin biosynthesis which, if untreated, result in motor and cognitive symptoms including impairment of EF. A comprehensive neuropsychological test battery was administered to six participants with BH4 deficiency (four males, two females, mean Full-scale intelligence quotient [FIQ] 63.8 [SD 14.7]); all were on replacement therapy with L-dopa and BH4, but time of initiation of treatment varied. Age range (median) was 28 days to 41 years (2y 6mo) at initiation of treatment and 10 to 47 years (19y) at follow-up. On non-EF tests, performance agreed with those of IQ-matched controls (four males, two females; mean age 16y 6mo [SD 6mo]; mean FIQ 62.3 [SD 13.4]). On EF tests those who initiated treatment after 2 years 6 months of age performed poorly. In patients with BH4 deficiency, replacement therapy should be started in the first weeks or months of life. Patients diagnosed before the age of 2 years 6 months obtain normal EF, which suggests dopamine may play a critical role in ensuring stable development of EF in early life.",
author = "Yoko Tanaka and Motoichiro Kato and Taro Muramatsu and Fumie Saito and Seiji Sato and Nobutake Matsuo and Haruo Shintaku and Yoshiyuki Okano and Hiroshi Kondo and Tatsushi Nukazawa",
year = "2007",
month = "5",
doi = "10.1111/j.1469-8749.2007.00372.x",
language = "English",
volume = "49",
pages = "372--376",
journal = "Developmental Medicine and Child Neurology",
issn = "0012-1622",
publisher = "Wiley-Blackwell",
number = "5",

}

TY - JOUR

T1 - Early initiation of L-dopa therapy enables stable development of executive function in tetrahydrobiopterin (BH4) deficiency

AU - Tanaka, Yoko

AU - Kato, Motoichiro

AU - Muramatsu, Taro

AU - Saito, Fumie

AU - Sato, Seiji

AU - Matsuo, Nobutake

AU - Shintaku, Haruo

AU - Okano, Yoshiyuki

AU - Kondo, Hiroshi

AU - Nukazawa, Tatsushi

PY - 2007/5

Y1 - 2007/5

N2 - Executive function (EF) has been presumed to be mediated by the dopaminergic system in the prefrontal cortex. However, little is known about the early development of this function and the roles dopamine plays in it. Tetrahydrobiopterin (BH4) deficiencies are genetic disorders affecting catecholamine and serotonin biosynthesis which, if untreated, result in motor and cognitive symptoms including impairment of EF. A comprehensive neuropsychological test battery was administered to six participants with BH4 deficiency (four males, two females, mean Full-scale intelligence quotient [FIQ] 63.8 [SD 14.7]); all were on replacement therapy with L-dopa and BH4, but time of initiation of treatment varied. Age range (median) was 28 days to 41 years (2y 6mo) at initiation of treatment and 10 to 47 years (19y) at follow-up. On non-EF tests, performance agreed with those of IQ-matched controls (four males, two females; mean age 16y 6mo [SD 6mo]; mean FIQ 62.3 [SD 13.4]). On EF tests those who initiated treatment after 2 years 6 months of age performed poorly. In patients with BH4 deficiency, replacement therapy should be started in the first weeks or months of life. Patients diagnosed before the age of 2 years 6 months obtain normal EF, which suggests dopamine may play a critical role in ensuring stable development of EF in early life.

AB - Executive function (EF) has been presumed to be mediated by the dopaminergic system in the prefrontal cortex. However, little is known about the early development of this function and the roles dopamine plays in it. Tetrahydrobiopterin (BH4) deficiencies are genetic disorders affecting catecholamine and serotonin biosynthesis which, if untreated, result in motor and cognitive symptoms including impairment of EF. A comprehensive neuropsychological test battery was administered to six participants with BH4 deficiency (four males, two females, mean Full-scale intelligence quotient [FIQ] 63.8 [SD 14.7]); all were on replacement therapy with L-dopa and BH4, but time of initiation of treatment varied. Age range (median) was 28 days to 41 years (2y 6mo) at initiation of treatment and 10 to 47 years (19y) at follow-up. On non-EF tests, performance agreed with those of IQ-matched controls (four males, two females; mean age 16y 6mo [SD 6mo]; mean FIQ 62.3 [SD 13.4]). On EF tests those who initiated treatment after 2 years 6 months of age performed poorly. In patients with BH4 deficiency, replacement therapy should be started in the first weeks or months of life. Patients diagnosed before the age of 2 years 6 months obtain normal EF, which suggests dopamine may play a critical role in ensuring stable development of EF in early life.

UR - http://www.scopus.com/inward/record.url?scp=34248564598&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=34248564598&partnerID=8YFLogxK

U2 - 10.1111/j.1469-8749.2007.00372.x

DO - 10.1111/j.1469-8749.2007.00372.x

M3 - Article

C2 - 17489812

AN - SCOPUS:34248564598

VL - 49

SP - 372

EP - 376

JO - Developmental Medicine and Child Neurology

JF - Developmental Medicine and Child Neurology

SN - 0012-1622

IS - 5

ER -